AU2019393784B2 - Compounds for the treatment of arenavirus infection - Google Patents
Compounds for the treatment of arenavirus infection Download PDFInfo
- Publication number
- AU2019393784B2 AU2019393784B2 AU2019393784A AU2019393784A AU2019393784B2 AU 2019393784 B2 AU2019393784 B2 AU 2019393784B2 AU 2019393784 A AU2019393784 A AU 2019393784A AU 2019393784 A AU2019393784 A AU 2019393784A AU 2019393784 B2 AU2019393784 B2 AU 2019393784B2
- Authority
- AU
- Australia
- Prior art keywords
- compound
- independently selected
- alkyl
- pharmaceutically acceptable
- halogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
- C07D249/18—Benzotriazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862776390P | 2018-12-06 | 2018-12-06 | |
| US62/776,390 | 2018-12-06 | ||
| PCT/US2019/064223 WO2020117794A1 (en) | 2018-12-06 | 2019-12-03 | Compounds for the treatment of arenavirus infection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2019393784A1 AU2019393784A1 (en) | 2021-05-27 |
| AU2019393784B2 true AU2019393784B2 (en) | 2025-06-12 |
Family
ID=70975517
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019393784A Active AU2019393784B2 (en) | 2018-12-06 | 2019-12-03 | Compounds for the treatment of arenavirus infection |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP3890731A4 (https=) |
| JP (1) | JP7675009B2 (https=) |
| KR (1) | KR20210106997A (https=) |
| CN (1) | CN113329750B (https=) |
| AR (1) | AR117228A1 (https=) |
| AU (1) | AU2019393784B2 (https=) |
| BR (1) | BR112021010909A2 (https=) |
| EA (1) | EA202191001A1 (https=) |
| MX (2) | MX2021005234A (https=) |
| WO (1) | WO2020117794A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116217490B (zh) * | 2023-02-03 | 2025-09-26 | 中国人民解放军军事科学院军事医学研究院 | 一种苯并咪唑类化合物及其制备方法和应用 |
| EP4434972A1 (en) * | 2023-03-22 | 2024-09-25 | Eberhard-Karls-Universität Tübingen | Atm kinase inhibitors |
| WO2025137345A1 (en) * | 2023-12-20 | 2025-06-26 | Arisan Therapeutics Inc. | Crystalline forms of an imidazopyridine derivative |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018013430A2 (en) * | 2016-07-12 | 2018-01-18 | Arisan Therapeutics Inc. | Heterocyclic compounds for the treatment of arenavirus infection |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2293638T3 (es) * | 1994-03-25 | 2008-03-16 | Isotechnika, Inc. | Mejora de la eficacia de farmacos por deuteracion. |
| WO2012065297A1 (en) * | 2010-11-16 | 2012-05-24 | Impact Therapeutics, Inc. | 3-ARYL-6-ARYL-[1,2,4]TRIAZOLO[4,3-a]PYRIDINES AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF |
| AP3675A (en) * | 2012-02-17 | 2016-04-15 | Kineta Four Llc | Antiviral drugs for treatment of arenavirus infection |
| US9688680B2 (en) | 2014-08-04 | 2017-06-27 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
-
2019
- 2019-12-02 AR ARP190103517A patent/AR117228A1/es unknown
- 2019-12-03 MX MX2021005234A patent/MX2021005234A/es unknown
- 2019-12-03 CN CN201980080594.2A patent/CN113329750B/zh active Active
- 2019-12-03 EA EA202191001A patent/EA202191001A1/ru unknown
- 2019-12-03 EP EP19892030.8A patent/EP3890731A4/en active Pending
- 2019-12-03 WO PCT/US2019/064223 patent/WO2020117794A1/en not_active Ceased
- 2019-12-03 AU AU2019393784A patent/AU2019393784B2/en active Active
- 2019-12-03 JP JP2021525159A patent/JP7675009B2/ja active Active
- 2019-12-03 BR BR112021010909-9A patent/BR112021010909A2/pt unknown
- 2019-12-03 KR KR1020217017726A patent/KR20210106997A/ko not_active Ceased
-
2021
- 2021-05-04 MX MX2024013042A patent/MX2024013042A/es unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018013430A2 (en) * | 2016-07-12 | 2018-01-18 | Arisan Therapeutics Inc. | Heterocyclic compounds for the treatment of arenavirus infection |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3890731A4 (en) | 2022-08-17 |
| MX2021005234A (es) | 2021-08-11 |
| JP2022509763A (ja) | 2022-01-24 |
| MX2024013042A (es) | 2024-12-06 |
| CA3118765A1 (en) | 2020-06-11 |
| EA202191001A1 (ru) | 2021-08-16 |
| CN113329750B (zh) | 2025-10-17 |
| AU2019393784A1 (en) | 2021-05-27 |
| EP3890731A1 (en) | 2021-10-13 |
| JP7675009B2 (ja) | 2025-05-12 |
| WO2020117794A1 (en) | 2020-06-11 |
| CN113329750A (zh) | 2021-08-31 |
| BR112021010909A2 (pt) | 2021-08-24 |
| KR20210106997A (ko) | 2021-08-31 |
| AR117228A1 (es) | 2021-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11352328B2 (en) | Heterocyclic compounds for the treatment of arenavirus | |
| AU2018331172B2 (en) | Influenza virus replication inhibitor and use thereof | |
| US11548893B2 (en) | Enantiomerically pure adamantane carboxamides for the treatment of filovirus infection | |
| CN114057702B (zh) | 一种新型冠状病毒主蛋白酶的抑制剂及其制备方法和用途 | |
| US12240857B2 (en) | Adamantane derivatives for the treatment of filovirus infection | |
| AU2019393784B2 (en) | Compounds for the treatment of arenavirus infection | |
| CN109415367A (zh) | 用于治疗和预防乙型肝炎病毒感染的新的二氢吡咯并嘧啶类化合物 | |
| BR112014007134B1 (pt) | Usos de um composto da fórmula (b), compostos, composição farmacêutica, método de preparação do composto e uso do composto para fabricação de um medicamento para tratar ou prevenir infecções flavivirais | |
| EP2997028A1 (en) | Aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection | |
| US12358897B2 (en) | Compounds and method of treating COVID-19 | |
| EP3544961B1 (en) | Positive allosteric modulators of the muscarinic acetylcholine receptor m4 | |
| JP6859358B2 (ja) | テトラヒドロインダゾール及びその医学的使用 | |
| US12419865B2 (en) | Compounds for the treatment of arenavirus infection | |
| CA3118765C (en) | Compounds for the treatment of arenavirus infection | |
| KR101850142B1 (ko) | 1-(3-아미노프로필) 치환 고리형 아민계 화합물, 이의 제조방법, 약물 조성물 및 용도 | |
| OA20266A (https=) | ||
| EA044865B1 (ru) | Соединения для лечения аренавирусной инфекции | |
| WO2021262426A9 (en) | Adamantane amides and thioamides for the treatment of ebolavirus infection | |
| JPH09301976A (ja) | ２−アリール−５，１１−ジヒドロ−６Ｈ−ジピリド［３，２−ｂ：２′，３′−ｅ］［１，４］ジアゼピン及びＨＩＶ感染の治療におけるその使用 | |
| CN121270547A (zh) | 一类酰胺类化合物及其制备方法、药物组合物和用途 | |
| HK40014598B (en) | Positive allosteric modulators of the muscarinic acetylcholine receptor m4 | |
| HK40014598A (en) | Positive allosteric modulators of the muscarinic acetylcholine receptor m4 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |